- Home
- GILD vs LLY Comparison
GILD vs LLY Comparison
Compare GILD & LLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | LLY |
|---|---|---|
| Founded | 1987 | 1876 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4B | 950.7B |
| IPO Year | 2000 | 2007 |
Fundamental Metrics
Financial Performance| Metric | GILD | LLY |
|---|---|---|
| Price | $145.31 | $987.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 19 |
| Target Price | $146.50 | ★ $1,174.53 |
| AVG Volume (30 Days) | ★ 5.2M | 2.3M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.26% | 0.70% |
| EPS Growth | ★ 1684.21 | 95.99 |
| EPS | 6.78 | ★ 22.95 |
| Revenue | $24,689,000,000.00 | ★ $65,179,000,000.00 |
| Revenue This Year | $4.68 | $27.04 |
| Revenue Next Year | $6.10 | $16.26 |
| P/E Ratio | ★ $21.38 | $42.96 |
| Revenue Growth | 9.98 | ★ 44.70 |
| 52 Week Low | $95.30 | $623.78 |
| 52 Week High | $157.29 | $1,133.95 |
Technical Indicators
Market Signals| Indicator | GILD | LLY |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 43.20 |
| Support Level | $142.93 | $978.77 |
| Resistance Level | $157.29 | $1,102.49 |
| Average True Range (ATR) | 3.24 | 23.87 |
| MACD | -0.99 | -2.25 |
| Stochastic Oscillator | 32.52 | 24.62 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.